EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expanding arsenal of type III CRISPR-Cas antiviral defense

Irmantas Mogila, Dalia Smalakyte, Gintautas Tamulaitis iD

FEMS Microbiology Reviews · 04.11.2026

DOI: 10.1093/femsre/fuag057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEMS Microbiology Reviews, online erschienen am 04.11.2026. Verfasst von Irmantas Mogila und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio Ave. 7, 10257 Vilnius, Lithuania. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR-Cas systems are adaptive immune systems that protect prokaryotes from invading genetic elements through acquisition of foreign nucleic acid sequences and RNA-guided recognition of target molecules. Among the diverse CRISPR-Cas families, type III systems represent a highly complex and versatile branch that couples sequence-specific interference with nucleotide-based signaling and activation of diverse downstream immune responses. Recent discoveries have substantially expanded the functional diversity of type III CRISPR-Cas systems, revealing new subtypes, ancillary effectors, nucleotide second messengers, signal-degrading enzymes, and viral counter-defense strategies. Here, we summarize current mechanistic and structural insights into type III CRISPR-Cas biology, from adaptation and target recognition to immune signaling, ancillary effector-mediated responses, and defense regulation. We further discuss emerging biotechnological applications of type III systems and highlight key unanswered questions shaping future research in this rapidly evolving field.

Schlagwörter

Stichwörter der Autor:innen

CARFCRISPR-CasCas10cyclic nucleotidering nucleasesignaling

Autor:innen und Institutionen

  • Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio Ave. 7, 10257 Vilnius, Lithuania.

ORCID-Profile: Gintautas Tamulaitis

Zitieren

APA

Mogila, I., Smalakyte, D., & Tamulaitis, G. (2026). Expanding arsenal of type III CRISPR-Cas antiviral defense. FEMS Microbiology Reviews. https://doi.org/10.1093/femsre/fuag057

Vancouver

Mogila I, Smalakyte D, Tamulaitis G. Expanding arsenal of type III CRISPR-Cas antiviral defense. FEMS Microbiology Reviews. 2026. doi:10.1093/femsre/fuag057

BibTeX
@article{Mogila2026,
  author = {Mogila, Irmantas and Smalakyte, Dalia and Tamulaitis, Gintautas},
  title = {Expanding arsenal of type III CRISPR-Cas antiviral defense},
  journal = {FEMS Microbiology Reviews},
  year = {2026},
  doi = {10.1093/femsre/fuag057}
}
Kostenlos starten →